The Glasgow Precision Oncology Laboratory (GPOL) at the University of Glasgow has developed a ground-breaking new cancer test for research and clinical trials that could ultimately change the way cancer medicine is delivered. The Glasgow Cancer Tests are a suite of affordable solid tumour and blood cancer tests, developed specifically to enable patients to benefit from real-world precision medicine-based cancer treatments. The Glasgow Cancer Tests...
Researchers at the University of Dundee have made a discovery they believe has the potential to put the brakes on the ‘runaway train’ that is Parkinson’s disease. The team, based at the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) in the School of Life Sciences, have discovered a new enzyme that inhibits the LRRK2 pathway. Mutations of the LRRK2 gene are the most...
Scientists have found that a pair of molecules – one in nerves and one in muscles – need to bind in order for the contact points, known as synapses, to form properly. Without this connection, growing nerves cannot advance during development of the embryo and communication between nerve and muscle is disrupted. Developing treatments The findings offer clues for developing treatments that could help patients...
Ubiquigent Limited (Ubiquigent) and LEO Pharma A/S announced today that they have entered into an option agreement granting LEO Pharma access to two novel compounds. Today’s announcement follows on from an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation. Under the terms of this latest agreement LEO Pharma will pay Ubiquigent an upfront fee, followed by a further fee...
The Digital Health and Care Institute is working in collaboration with the Scottish Government to launch the next research and development phase of the innovative decision support programme. This programme supports use of information and artificial intelligence in decision making by frontline health and care staff, and in better self-management of health by Scottish citizens. As a springboard for this latest phase, the decision support...
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces an update on progress in its Phase IIa clinical study. MGB-BP-3 is a potent bactericidal antibiotic with a completely novel mode of action. An oral formulation is being developed specifically for the treatment of Clostridium difficile-associated disease (CDAD). MGB Biopharma’s ongoing Phase IIa...